Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.
RockyKanaka on MSN3h
Senior Yorkie Was Just About to Be Adopted—Then She Collapsed and was Rushed to the ERRight before her adoption, Piper, a senior Yorkie, suffered liver failure. She was rushed to the ER and is now receiving the ...
Announcing a new publication for Acta Materia Medica journal. Excessive consumption of acetaminophen (APAP) has emerged as the primary culprit behind drug-induced liver injury (DILI), with ...
Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...
It is often assumed that because herbal pills are derived from natural sources, they can be used without restrictions on ...
Liverpool manager Arne Slot praised Pep Guardiola’s management of his injury-hit Manchester City side and raised his own ...
Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.
One place this happens is around the belly button, where tiny veins in the abdominal wall expand and become visible under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback